CooperCompanies Q3 adjusted EPS beats estimates

The Cooper Companies

27/08/2025 21:24

Overview

CooperCompanies fiscal Q3 revenue rises 6% yr/yr to $1,060.3 mln, meets expectations, per LSEG data

Non-GAAP diluted EPS up 15% to $1.10, beating analyst expectations, per LSEG data

Co repurchased $52.1 mln of shares, $163.6 mln remains in buyback program

Outlook

CooperCompanies raises fiscal 2025 non-GAAP EPS guidance to $4.08 - $4.12

Company expects Q4 2025 revenue of $1,049 - $1,069 mln

CVI revenue forecasted at $700- $713 mln for Q4 2025

CSI revenue projected at $350 - $356 mln for Q4 2025

Result Drivers

PRODUCT LINE EXIT - CooperSurgical's gross and operating margins were impacted by a product line exit, reducing GAAP margins

EFFICIENCY GAINS - Non-GAAP gross margin improved by 70 basis points due to efficiency gains and favorable foreign exchange

REVENUE GROWTH - CooperVision revenue grew 6% driven by strong performance in Toric and multifocal lenses

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
In-line
$1.06 bln
$1.06 bln (14 Analysts)
Q3 Adjusted EPS
Beat
$1.1
$1.07 (15 Analysts)
Q3 EPS
$0.49
Q3 Gross Margin
65.0%
Q3 EBIT Margin
17.0%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Cooper Companies Inc is $94.00, about 21.6% above its August 26 closing price of $73.66

Press Release: ID:nGNX6sfVJC

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)